ClinicalTrials.gg
TerminatedNCT03245840Updated Feb 19, 2025Results posted

Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE)

A Phase 3 interventional study of Budesonide oral suspension in Eosinophilic Esophagitis (EoE), sponsored by Shire. Terminated at 45 sites in United States. Open to participants aged 11 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-02-19.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Why this study was terminated
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
133
Allocation
Not applicable
Ages
11 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing budesonide in Eosinophilic Esophagitis — 1 open to participants now, 2 under way, 1 of them phase 3. Budesonide · Eosinophilic Esophagitis.

Enrollment
5th of 18
133 · median 79
Started
2017
the only one that year
Phase 3
6 of 18
none open now
Registered
14th of 18
by date
Lead sponsor
5 of 18
Shire

Among the 18 studies testing budesonide in Eosinophilic Esophagitis, this one is the 5th largest by enrollment, is the only one that started in 2017, is one of 6 in phase 3, and was the 14th registered.

Eosinophilic Esophagitis

235 studies on the registry are indexed under Eosinophilic Esophagitis; 53 are open to participants now.

Browse Eosinophilic Esophagitis studies →

Open to participants now

1 of the 18 studies testing budesonide in Eosinophilic Esophagitis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 42 Eosinophilic Esophagitis studies recruiting now, 12 (29%) set no upper age limit and 27 (64%) stop at 75 or younger; 27 take children under 18; 7 take healthy volunteers.

This study: 11 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing budesonide in Eosinophilic Esophagitis, or all of them as a file.
02

Study summary

This is a continuation study of Budesonide Oral Suspension (BOS) in adults and adolescents with Eosinophilic Esophagitis (EoE) who have completed participation in the SHP621-302 extension study. The purpose of this study is to see if BOS is safe and well tolerated over the long-term in adolescents and adults with EoE.

03

Conditions studied

  • Eosinophilic Esophagitis (EoE)
04

Who can participate

Ages eligible
11 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant completed the SHP621-302 (NCT02736409) extension study and is considered by the investigator to potentially benefit from continued BOS treatment.
  • Participant is able to provide written (participant, parent or legal guardian and, as appropriate, participant assent) to participate in the study before completing any study-related procedures.
  • Females of must agree to continue acceptable measures (example (e.g.): abstinence, surgically sterile male partner, stable oral contraceptives, or double-barrier methods) throughout study participation.
  • Participant is willing and has an understanding and ability to fully comply with study procedures and restrictions as defined in protocol.

Exclusion criteria

Exclusion Criteria:

  • Participant has changes in medications or diet during the SHP621-302 (NCT02736409) study that could affect participation in this continuation study.
  • Participant anticipates using swallowed topical for EoE or systemic corticosteroid for any condition during the treatment period; any temporary use (less than or equal to [≤] 7 days) or initiation of new steroid treatment during the study should be documented and discussed with the medical monitor prospectively but should be avoided within 4 weeks of the scheduled esophagogastroduodenoscopy (EGDs).
  • Participant anticipates use of Cytochrome P450 3A4 inhibitors (e.g., ketoconazole, grapefruit juice) during the continuation study.
  • Participant has an appearance at the EGD at the final treatment evaluation visit of SHP621-302 (NCT02736409) (Visit 8) of an esophageal stricture (high grade), as defined by the presence of a lesion that does not allow passage of a diagnostic adult upper endoscope (e.g., with an insertion tube diameter of greater than (>) 9 millimeter [mm]).
  • Participant has presence of esophageal varices at the EGD at the final treatment evaluation visit (Visit 8) of the SHP621-302 (NCT02736409) study.
  • Participant has any current disease of the gastrointestinal tract, aside from EoE, including eosinophilic gastritis, enteritis, colitis, or proctitis, inflammatory bowel disease, or celiac disease.
  • Participant has other diseases causing or associated with esophageal eosinophilia, including hypereosinophilic syndrome, collagen vascular disease, vasculitis, achalasia, or parasitic infection.
  • Participant has oropharyngeal or esophageal candidiasis that failed to respond to previous treatment. Diagnosis with oropharyngeal or esophageal candidiasis at or since the final treatment evaluation visit (Visit 8) of the SHP621-302 (NCT02736409) study is not an exclusion as long as the participant is expected to respond to treatment.
  • Participant has a potentially serious acute or chronic infection or immunodeficiency condition, including tuberculosis, fungal, bacterial, viral/parasite infection, ocular herpes simplex, or chicken pox/measles.
  • Participant has upper gastrointestinal bleeding identified at the EGD at the final treatment evaluation visit (Visit 8) of the SHP621-302 (NCT02736409) study.
  • Participant has evidence of active infection with Helicobacter pylori.
  • Participant has evidence of unstable asthma.
  • Participant is female and pregnant or nursing.
  • Participant has a history of intolerance, , or idiosyncratic reaction to budesonide (or any other corticosteroids), or to any other ingredients of the study medication.
  • Participant has a history or high risk of noncompliance with treatment or regular clinic visits.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
133 participants (actual)

Study arms

  • Experimental
    Budesonide Oral Suspension

    Participants received 10 milliliters (mL) of budesonide oral suspension at a concentration of 0.2 milligram per milliliter (mg/mL), twice daily, for up to 4 years 5 months.

    Drug: Budesonide oral suspension

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

    An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. A Serious Adverse Event (SAE) was any untoward medical occurrence (whether considered to be related to investigational product or not) that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital abnormality/birth defect, and is an important medical event. Both serious and Non-serious TEAEs were reported in this outcome measure. TEAEs were defined as AEs with a start date on or after the first dose of investigational product or a start date before the date of the first dose of investigational product that increased in severity or after the date of the first dose.

    Time frame: From start of study drug administration up to End of study (EOS) (Up to Month 53)

  2. Number of Participants With Clinically Significant Physical Examination Findings

    Number of participants with clinically significant physical examination findings were reported. Clinical significance was determined by investigator.

    Time frame: From start of study drug administration up to EOS (Up to Month 53)

  3. Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    Participants were assessed by investigator for any clinically significant changes in vital parameters like temperature, systolic and diastolic blood pressure, pulse, respiratory rate, BMI, and weight. Vital signs were assessed after the participant had been in a supine position for at least 5 minutes immediately prior to the assessment. The criteria for clinically significant change was as per the investigators discretion.

    Time frame: From start of study drug administration up to EOS (Up to Month 53)

  4. Change From Baseline in Bone Mineral Density (BMD) For Adolescents Assessed by Dual-Energy X-ray Absorptiometry (DXA) Scan at Month 12

    The sites for DXA measurement were the lumbar spine at lumbar vertebrae 1 to 4 (L1-L4) and whole body. DXA scans for determination of BMD and body composition was performed in participants aged 11-17 years. Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. In this study, the BMD Z-score is considered abnormal when the z-score is less than (\<) -2, suggesting a worse outcome (i.e., osteoporosis). Change from baseline in BMD for adolescents assessed by DXA Scan at Month 12 was reported.

    Time frame: Baseline, Month 12

  5. Change From Baseline in BMD For Adolescents Assessed by DXA Scan at Month 24

    The sites for DXA measurement were the lumbar spine at lumbar vertebrae 1 to 4 (L1-L4) and whole body. DXA scans for determination of BMD and body composition was performed in participants aged 11-17 years. Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. In this study, the BMD Z-score is considered abnormal when the z-score is \<-2, suggesting a worse outcome (i.e., osteoporosis) and vice versa. Change from baseline in BMD for adolescents assessed by DXA Scan at Month 24 was reported.

    Time frame: Baseline, Month 24

  6. Change From Baseline in BMD For Adolescents Assessed by DXA Scan at Month 36

    The sites for DXA measurement were the lumbar spine at lumbar vertebrae 1 to 4 (L1-L4) and whole body. DXA scans for determination of BMD and body composition was performed in participants aged 11-17 years. Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. In this study, the BMD Z-score is considered abnormal when the z-score is \< -2, suggesting a worse outcome (i.e., osteoporosis) and vice versa. Change from baseline in BMD for adolescents assessed by DXA Scan at Month 36 was reported.

    Time frame: Baseline, Month 36

  7. Change From Baseline in BMD For Adolescents Assessed by DXA Scan at Month 48

    The sites for DXA measurement were the lumbar spine at lumbar vertebrae 1 to 4 (L1-L4) and whole body. DXA scans for determination of BMD and body composition was performed in participants aged 11-17 years. Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. In this study, the BMD Z-score is considered abnormal when the z-score is \< -2, suggesting a worse outcome (i.e., osteoporosis) and vice versa. Change from baseline in BMD for adolescents assessed by DXA Scan at Month 48 was reported.

    Time frame: Baseline, Month 48

  8. Change From Baseline in BMD For Adolescents Assessed by DXA Scan at EOS (Up to Month 53)

    The sites for DXA measurement were the lumbar spine at lumbar vertebrae 1 to 4 (L1-L4) and whole body. DXA scans for determination of BMD and body composition was performed in participants aged 11-17 years. Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. In this study, the BMD Z-score is considered abnormal when the z-score is \< -2, suggesting a worse outcome (i.e., osteoporosis) and vice versa. Change from baseline in BMD for adolescents assessed by DXA Scan at EOS (up to Month 53) was reported.

    Time frame: Baseline, EOS (Up to Month 53)

  9. Change From Baseline in Cortisol Level After Adrenocorticotropic Hormone (ACTH) Stimulation at Month 12

    ACTH testing was a standard procedure to measure the levels of cortisol in the blood following the injection of a synthetic form of ACTH (250 microgram \[mcg\]). The type of synthetic and route of administration was per investigator discretion. The change from baseline in cortisol levels was calculated at Month 12 and reported in this outcome measure.

    Time frame: Baseline, Month 12

  10. Change From Baseline in Cortisol Level After ACTH Stimulation at Month 24

    ACTH testing was a standard procedure to measure the levels of cortisol in the blood following the injection of a synthetic form of ACTH (250 microgram \[mcg\]). The type of synthetic and route of administration was per investigator discretion. The change from baseline in cortisol levels was calculated at Month 24 and reported in this outcome measure.

    Time frame: Baseline, Month 24

  11. Change From Baseline in Cortisol Level After ACTH Stimulation at Month 36

    ACTH testing was a standard procedure to measure the levels of cortisol in the blood following the injection of a synthetic form of ACTH (250 microgram \[mcg\]). The type of synthetic and route of administration was per investigator discretion. The change from baseline in cortisol levels was calculated at Month 36 and reported in this outcome measure.

    Time frame: Baseline, Month 36

  12. Change From Baseline in Cortisol Level After ACTH Stimulation at Month 48

    ACTH testing was a standard procedure to measure the levels of cortisol in the blood following the injection of a synthetic form of ACTH (250 microgram \[mcg\]). The type of synthetic and route of administration was per investigator discretion. The change from baseline in cortisol levels was calculated at Month 48 and reported in this outcome measure.

    Time frame: Baseline, Month 48

  13. Change From Baseline in Cortisol Level After ACTH Stimulation at EOS (Up to Month 53)

    ACTH testing was a standard procedure to measure the levels of cortisol in the blood following the injection of a synthetic form of ACTH (250 microgram \[mcg\]). The type of synthetic and route of administration was per investigator discretion. The change from baseline in cortisol levels was calculated at EOS (up to Month 53) and reported in this outcome measure.

    Time frame: Baseline, EOS (Up to Month 53)

  14. Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments

    Clinical laboratory parameters included hematology, chemistry, urinalysis; urine pregnancy test. Number of participants with potential clinically significant changes in laboratory parameters which were deemed clinically meaningful by the investigator were reported.

    Time frame: From start of study drug administration up to EOS (Up to Month 53)

07

Results

Posted Dec 7, 2022
Limitations and caveats
The study was discontinued prematurely as per sponsor's decision.

Participant flow

This study was conducted at 44 active sites in North America from 05 October 2017 (first participant enrolled) to 26 April 2022 (last participant completed).

Participant flow — Overall Study
MilestoneBOS-BOSPBO-BOS
Started12211
Treated12110
Completed00
Not completed12211
Withdrew: Adverse event60
Withdrew: Death20
Withdrew: Withdrawal by subject311
Withdrew: Withdrawal by parent/guardian20
Withdrew: Physician decision41
Withdrew: Study terminated by sponsor566
Withdrew: Site terminated by sponsor40
Withdrew: Lost to follow-up122
Withdrew: Pregnancy20
Withdrew: Non-compliance with study drug20
Withdrew: Not treated11

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. A Serious Adverse Event (SAE) was any untoward medical occurrence (whether considered to be related to investigational product or not) that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital abnormality/birth defect, and is an important medical event. Both serious and Non-serious TEAEs were reported in this outcome measure. TEAEs were defined as AEs with a start date on or after the first dose of investigational product or a start date before the date of the first dose of investigational product that increased in severity or after the date of the first dose.

Time frame:
From start of study drug administration up to End of study (EOS) (Up to Month 53)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsBOS-BOSPBO-BOS
TEAEs937
Serious TEAEs110
PrimaryNumber of Participants With Clinically Significant Physical Examination Findings

Number of participants with clinically significant physical examination findings were reported. Clinical significance was determined by investigator.

Time frame:
From start of study drug administration up to EOS (Up to Month 53)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Physical Examination Findings
ParticipantsBOS-BOSPBO-BOS
Moon Face00
Acne20
Hirsutism00
Mood swings00
Insomnia00
Depression10
PrimaryNumber of Participants With Clinically Significant Change From Baseline in Vital Signs

Participants were assessed by investigator for any clinically significant changes in vital parameters like temperature, systolic and diastolic blood pressure, pulse, respiratory rate, BMI, and weight. Vital signs were assessed after the participant had been in a supine position for at least 5 minutes immediately prior to the assessment. The criteria for clinically significant change was as per the investigators discretion.

Time frame:
From start of study drug administration up to EOS (Up to Month 53)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
ParticipantsBOS-BOSPBO-BOS
Number of Participants With Clinically Significant Change From Baseline in Vital Signs00
PrimaryChange From Baseline in Bone Mineral Density (BMD) For Adolescents Assessed by Dual-Energy X-ray Absorptiometry (DXA) Scan at Month 12

The sites for DXA measurement were the lumbar spine at lumbar vertebrae 1 to 4 (L1-L4) and whole body. DXA scans for determination of BMD and body composition was performed in participants aged 11-17 years. Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. In this study, the BMD Z-score is considered abnormal when the z-score is less than (\<) -2, suggesting a worse outcome (i.e., osteoporosis). Change from baseline in BMD for adolescents assessed by DXA Scan at Month 12 was reported.

Time frame:
Baseline, Month 12
Reported as:
Mean · Z-score
Change From Baseline in Bone Mineral Density (BMD) For Adolescents Assessed by Dual-Energy X-ray Absorptiometry (DXA) Scan at Month 12
Z-scoreBOS-BOS
Baseline Lumbar Spine (L1- L4)-0.525 ± 1.0583
Change at Month 12 Lumbar Spine (L1- L4)0.315 ± 0.3618
Baseline Whole Body-0.565 ± 0.9464
Change at Month 12 Whole Body0.250 ± 0.2599
PrimaryChange From Baseline in BMD For Adolescents Assessed by DXA Scan at Month 24

The sites for DXA measurement were the lumbar spine at lumbar vertebrae 1 to 4 (L1-L4) and whole body. DXA scans for determination of BMD and body composition was performed in participants aged 11-17 years. Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. In this study, the BMD Z-score is considered abnormal when the z-score is \<-2, suggesting a worse outcome (i.e., osteoporosis) and vice versa. Change from baseline in BMD for adolescents assessed by DXA Scan at Month 24 was reported.

Time frame:
Baseline, Month 24
Reported as:
Mean · Z-score
Change From Baseline in BMD For Adolescents Assessed by DXA Scan at Month 24
Z-scoreBOS-BOS
Baseline Lumbar Spine (L1- L4)-0.525 ± 1.0583
Change at Month 24 Lumbar Spine (L1- L4)0.445 ± 0.7312
Baseline Whole Body-0.565 ± 0.9464
Change at Month 24 Whole Body0.092 ± 0.5326
PrimaryChange From Baseline in BMD For Adolescents Assessed by DXA Scan at Month 36

The sites for DXA measurement were the lumbar spine at lumbar vertebrae 1 to 4 (L1-L4) and whole body. DXA scans for determination of BMD and body composition was performed in participants aged 11-17 years. Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. In this study, the BMD Z-score is considered abnormal when the z-score is \< -2, suggesting a worse outcome (i.e., osteoporosis) and vice versa. Change from baseline in BMD for adolescents assessed by DXA Scan at Month 36 was reported.

Time frame:
Baseline, Month 36
Reported as:
Mean · Z-score
Change From Baseline in BMD For Adolescents Assessed by DXA Scan at Month 36
Z-scoreBOS-BOS
Baseline Lumbar Spine (L1- L4)-0.525 ± 1.0583
Change at Month 36 Lumbar Spine (L1- L4)0.603 ± 0.9089
Baseline Whole Body-0.565 ± 0.9464
Change at Month 36 Whole Body0.870 ± 0.6447
PrimaryChange From Baseline in BMD For Adolescents Assessed by DXA Scan at Month 48

The sites for DXA measurement were the lumbar spine at lumbar vertebrae 1 to 4 (L1-L4) and whole body. DXA scans for determination of BMD and body composition was performed in participants aged 11-17 years. Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. In this study, the BMD Z-score is considered abnormal when the z-score is \< -2, suggesting a worse outcome (i.e., osteoporosis) and vice versa. Change from baseline in BMD for adolescents assessed by DXA Scan at Month 48 was reported.

Time frame:
Baseline, Month 48
Reported as:
Mean · Z-score
Change From Baseline in BMD For Adolescents Assessed by DXA Scan at Month 48
Z-scoreBOS-BOS
Baseline Lumbar Spine (L1- L4)-0.525 ± 1.0583
Change at Month 48 Lumbar Spine (L1- L4)0.657 ± 0.4813
Baseline Whole Body-0.565 ± 0.9464
Change at Month 48 Whole Body0.817 ± 0.4521
PrimaryChange From Baseline in BMD For Adolescents Assessed by DXA Scan at EOS (Up to Month 53)

The sites for DXA measurement were the lumbar spine at lumbar vertebrae 1 to 4 (L1-L4) and whole body. DXA scans for determination of BMD and body composition was performed in participants aged 11-17 years. Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. In this study, the BMD Z-score is considered abnormal when the z-score is \< -2, suggesting a worse outcome (i.e., osteoporosis) and vice versa. Change from baseline in BMD for adolescents assessed by DXA Scan at EOS (up to Month 53) was reported.

Time frame:
Baseline, EOS (Up to Month 53)
Reported as:
Mean · Z-score
Change From Baseline in BMD For Adolescents Assessed by DXA Scan at EOS (Up to Month 53)
Z-scoreBOS-BOS
Baseline Lumbar Spine (L1- L4)-0.525 ± 1.0583
Change at EOS (Up to Month 53) Lumbar Spine (L1- L4)0.482 ± 0.6539
Baseline Whole Body-0.565 ± 0.9464
Change at EOS (Up to Month 53) Whole Body0.350 ± 0.7541
PrimaryChange From Baseline in Cortisol Level After Adrenocorticotropic Hormone (ACTH) Stimulation at Month 12

ACTH testing was a standard procedure to measure the levels of cortisol in the blood following the injection of a synthetic form of ACTH (250 microgram \[mcg\]). The type of synthetic and route of administration was per investigator discretion. The change from baseline in cortisol levels was calculated at Month 12 and reported in this outcome measure.

Time frame:
Baseline, Month 12
Reported as:
Mean · micrograms per deciliter (mcg/dL)
Change From Baseline in Cortisol Level After Adrenocorticotropic Hormone (ACTH) Stimulation at Month 12
micrograms per deciliter (mcg/dL)BOS-BOSPBO-BOS
Baseline10.49 ± 5.50813.15 ± 7.188
Change At Month 120.06 ± 6.2156.77 ± 8.835
PrimaryChange From Baseline in Cortisol Level After ACTH Stimulation at Month 24

ACTH testing was a standard procedure to measure the levels of cortisol in the blood following the injection of a synthetic form of ACTH (250 microgram \[mcg\]). The type of synthetic and route of administration was per investigator discretion. The change from baseline in cortisol levels was calculated at Month 24 and reported in this outcome measure.

Time frame:
Baseline, Month 24
Reported as:
Mean · mcg/dL
Change From Baseline in Cortisol Level After ACTH Stimulation at Month 24
mcg/dLBOS-BOSPBO-BOS
Baseline10.49 ± 5.50813.15 ± 7.188
Change At Month 240.81 ± 6.127-2.58 ± 3.727
PrimaryChange From Baseline in Cortisol Level After ACTH Stimulation at Month 36

ACTH testing was a standard procedure to measure the levels of cortisol in the blood following the injection of a synthetic form of ACTH (250 microgram \[mcg\]). The type of synthetic and route of administration was per investigator discretion. The change from baseline in cortisol levels was calculated at Month 36 and reported in this outcome measure.

Time frame:
Baseline, Month 36
Reported as:
Mean · mcg/dL
Change From Baseline in Cortisol Level After ACTH Stimulation at Month 36
mcg/dLBOS-BOSPBO-BOS
Baseline10.49 ± 5.50813.15 ± 7.188
Change At Month 360.70 ± 5.773-1.63 ± 3.845
PrimaryChange From Baseline in Cortisol Level After ACTH Stimulation at Month 48

ACTH testing was a standard procedure to measure the levels of cortisol in the blood following the injection of a synthetic form of ACTH (250 microgram \[mcg\]). The type of synthetic and route of administration was per investigator discretion. The change from baseline in cortisol levels was calculated at Month 48 and reported in this outcome measure.

Time frame:
Baseline, Month 48
Reported as:
Mean · mcg/dL
Change From Baseline in Cortisol Level After ACTH Stimulation at Month 48
mcg/dLBOS-BOSPBO-BOS
Baseline10.49 ± 5.50813.15 ± 7.188
Change At Month 482.02 ± 4.7590.20 ± 5.170
PrimaryChange From Baseline in Cortisol Level After ACTH Stimulation at EOS (Up to Month 53)

ACTH testing was a standard procedure to measure the levels of cortisol in the blood following the injection of a synthetic form of ACTH (250 microgram \[mcg\]). The type of synthetic and route of administration was per investigator discretion. The change from baseline in cortisol levels was calculated at EOS (up to Month 53) and reported in this outcome measure.

Time frame:
Baseline, EOS (Up to Month 53)
Reported as:
Mean · mcg/dL
Change From Baseline in Cortisol Level After ACTH Stimulation at EOS (Up to Month 53)
mcg/dLBOS-BOSPBO-BOS
Baseline10.49 ± 5.50813.15 ± 7.188
Change at EOS (Up to Month 53)0.96 ± 5.3621.06 ± 6.138
PrimaryNumber of Participants With Clinically Significant Changes in Clinical Laboratory Assessments

Clinical laboratory parameters included hematology, chemistry, urinalysis; urine pregnancy test. Number of participants with potential clinically significant changes in laboratory parameters which were deemed clinically meaningful by the investigator were reported.

Time frame:
From start of study drug administration up to EOS (Up to Month 53)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments
ParticipantsBOS-BOSPBO-BOS
Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments00

Adverse events

Collected over From start of study drug administration up to EOS (Up to Month 53). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BOS-BOS2/121 (1.7%)11/121 (9.1%)90/121 (74.4%)
PBO-BOS0/10 (0%)0/10 (0%)7/10 (70%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventBOS-BOSPBO-BOS
Cardiogenic shockCardiac disorders1/1210/10
Myocardial infarctionCardiac disorders1/1210/10
Oesophageal perforationGastrointestinal disorders1/1210/10
Anaphylactic reactionImmune system disorders1/1210/10
AppendicitisInfections and infestations1/1210/10
OverdoseInjury, poisoning and procedural complications1/1210/10
Spinal compression fractureInjury, poisoning and procedural complications1/1210/10
ObesityMetabolism and nutrition disorders1/1210/10
RhabdomyolysisMusculoskeletal and connective tissue disorders1/1210/10
Petit mal epilepsyNervous system disorders1/1210/10
Most frequent other events
Showing 10 of 30
Most frequent other events
EventBOS-BOSPBO-BOS
ACTH stimulation test abnormalInvestigations14/1210/10
Mitral valve incompetenceCardiac disorders0/1211/10
Tricuspid valve incompetenceCardiac disorders0/1211/10
NauseaGastrointestinal disorders4/1211/10
Oesophageal food impactionGastrointestinal disorders5/1211/10
Oesophageal stenosisGastrointestinal disorders2/1211/10
FatigueGeneral disorders1/1211/10
Drug hypersensitivityImmune system disorders0/1211/10
Seasonal allergyImmune system disorders0/1211/10
BronchitisInfections and infestations1/1211/10

Baseline characteristics

The safety analysis set (SAS) consisted of all participants who received at least 1 dose of BOS.

Age, Continuous
Age, Continuous(years)BOS-BOSPBO-BOSTotal
Mean33.9 ± 12.6540.2 ± 9.9734.4 ± 12.55
Age, Customized
Age, Customized(Participants)BOS-BOSPBO-BOSTotal
Less than 18 years22022
18 or more years9910109
Sex: Female, Male
Sex: Female, Male(Participants)BOS-BOSPBO-BOSTotal
Female47249
Male74882
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BOS-BOSPBO-BOSTotal
Hispanic or Latino303
Not Hispanic or Latino11710127
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BOS-BOSPBO-BOSTotal
American Indian or Alaska Native101
Asian000
Native Hawaiian or Other Pacific Islander101
Black or African American404
White10910119
More than one race000
Unknown or Not Reported606
08

Study locations

45 sites
  • Children's Hospital
    Birmingham, Alabama 35233, United States
  • Phoenix Childrens Hospital
    Phoenix, Arizona 85016, United States
  • Del Sol Research Management
    Tucson, Arizona 85712, United States
  • Arkansas Gastroenterology
    North Little Rock, Arkansas 72117, United States
  • Rady Children's Hospital San Diego
    San Diego, California 92123, United States
  • Colorado Children's Hospital
    Aurora, Colorado 80045, United States
  • Asthma and Allergy Associates PC
    Colorado Springs, Colorado 80907, United States
  • Rocky Mountain Pediatric Gastroenterology
    Denver, Colorado 80218, United States
  • Connecticut Clinical Research Foundation
    Bristol, Connecticut 06010, United States
  • Connecticut Children's Medical Center
    Hartford, Connecticut 06106, United States
  • Connecticut GI
    Hartford, Connecticut 06106, United States
  • Nature Coast Clinical Research LLC
    Inverness, Florida 34452, United States
  • Arnold Palmer Hospital for Children
    Orlando, Florida 32806, United States
  • Childrens Center For Digestive Healthcare
    Atlanta, Georgia 30342, United States
  • Gastroenterology Associates of Central Georgia
    Macon, Georgia 31201, United States
  • Grand Teton Research Group
    Idaho Falls, Idaho 83404, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Gastroenterology of Southern Indiana
    New Albany, Indiana 47150, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • Cotton O'Neil Clinical Research Center
    Topeka, Kansas 66606, United States
  • Indiana University
    Louisville, Kentucky 40202, United States
  • Gastroenterology Associates, LLC
    Baton Rouge, Louisiana 70809, United States
  • Clinical Trials Management LLC
    Metairie, Louisiana 70006, United States
  • Tufts Medical Center
    Boston, Massachusetts 00211, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Brigham and Womens Hospital
    Chestnut Hill, Massachusetts 02467, United States
  • Minnesota Gastroenterology PA
    Plymouth, Minnesota 55446, United States
  • Mount Sinai Hospital, Icahn School of Medicine
    Astoria, New York 11102, United States
  • Long Island Gastrointestinal Research Group LLP
    Great Neck, New York 11023, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27514, United States
  • Clinical Research of Charlotte
    Charlotte, North Carolina 28277, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Gastrointestinal and Liver Diseases Consultants PC
    Dayton, Ohio 45440, United States
  • Great Lakes Gastroenterology
    Mentor, Ohio 44060, United States
  • Digestive Disease Specialists, Inc.
    Oklahoma City, Oklahoma 73112, United States
  • Greenville Hospital
    Greenville, South Carolina 29615, United States
  • Gastro One
    Germantown, Tennessee 38138, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37212, United States
  • Houston Endoscopy and Research Center
    Houston, Texas 77024, United States
  • Advanced Research Institute
    Ogden, Utah 84405, United States
  • Primary Children's Hospital, University of Utah
    Salt Lake City, Utah 84132, United States
  • Emeritas Research Group
    Lansdowne Town Center, Virginia 20176, United States
  • Blue Ridge Medical Research
    Lynchburg, Virginia 24502, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — De-identified individual participant data from this particular study will not be shared as the data are subject to contractual (or consent) provisions that prohibit transfer to third parties.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Apr 2022, 54 months.

Results were first posted in Dec 2022, 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2017
First posted
Aug 10, 2017
StartActual
Oct 5, 2017
Primary completionActual
Apr 26, 2022
CompletionActual
Apr 26, 2022
Results first posted
Dec 7, 2022
Last update
Feb 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03245840
Lead sponsor
Shire
Collaborators
Takeda Development Center Americas, Inc.
Responsible party
Sponsor
First posted
Aug 10, 2017
Start date
Oct 5, 2017
Primary completion
Apr 26, 2022
Completion
Apr 26, 2022
Results posted
Dec 7, 2022
Last update
Feb 19, 2025

Study contacts

Study Director
study director · Shire

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion